<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508414</url>
  </required_header>
  <id_info>
    <org_study_id>NAMS-study</org_study_id>
    <nct_id>NCT03508414</nct_id>
  </id_info>
  <brief_title>Nutritional Approaches in Multiple Sclerosis</brief_title>
  <official_title>Nutritional Approaches in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to characterize the influence of a ketogenic diet and intermittent&#xD;
      therapeutical fasting on the course of the disease, as measured by T2-hyperintense cerebral&#xD;
      lesions with magnetic resonance tomography (MRT) in patients with multiple sclerosis (RRMS).&#xD;
      The investigators expect in both intervention groups fewer cerebral T2 lesions occurring&#xD;
      after 18 months in comparison to the control group and as detectable by MRT. According to&#xD;
      current recommendations of the German Society of Nutrition (DGE), the control group receives&#xD;
      a vegetarian-focused, anti-inflammatory diet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cerebral T2 lesions from Baseline at 18 months</measure>
    <time_frame>Change from baseline at 18 months</time_frame>
    <description>Number of new cerebral T2 lesions in MRT after 18 months compared to baseline MRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neurological-functional disability: physical and cognitive function</measure>
    <time_frame>Change from baseline at 9 and 18 months</time_frame>
    <description>influence of the interventions on cognitive and physical disability progression using Multiple Sclerosis Functional Composite (MSFC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurological-functional disability : physical function</measure>
    <time_frame>Change from baseline at 9 and 18 months</time_frame>
    <description>influence of the interventions on physical disability progression using Expanded Disability Status Score (EDSS). The EDSS is assessing the progress of disability in MS patients with a scale between 0-12 points, while 0 indicates no disability and 10 indicates death through MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>annual relapse rate</measure>
    <time_frame>12 months</time_frame>
    <description>relapse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress of brain atrophy</measure>
    <time_frame>Change from baseline at 18 months</time_frame>
    <description>PBVC = percent brain volume change</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ketogenic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent therapeutical fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ketogenic diet</intervention_name>
    <description>Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.</description>
    <arm_group_label>Ketogenic diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent therapeutical fasting</intervention_name>
    <description>Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.</description>
    <arm_group_label>Intermittent therapeutical fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active comparator</intervention_name>
    <description>The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Existing health insurance, so that in case of random findings these can also be&#xD;
             clarified&#xD;
&#xD;
          -  Patients with relapsed-remitting MS according to the MS diagnostic criteria according&#xD;
             to McDonald 2010&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Consent ability and written consent&#xD;
&#xD;
          -  BMI between 19 and 45 kg / m2&#xD;
&#xD;
          -  EDSS &lt;4.5&#xD;
&#xD;
          -  Stable immunomodulatory therapy or no immunomodulatory therapy&gt; 6 months before&#xD;
             confinement&#xD;
&#xD;
          -  In the last 2 years ≥ 1 relapse or within the last 2 years ≥ 1 new T2 lesions or ≥ 1&#xD;
             contrast-sensitive lesion in MRT&#xD;
&#xD;
          -  Consent that possible random findings are reported&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initiation or modification of immunomodulatory therapy during the study&#xD;
&#xD;
          -  Cortisone treatment in the last 30 days before enrollment&#xD;
&#xD;
          -  Relapse in the last 30 days before enrollment&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus (type I)&#xD;
&#xD;
          -  Intake of Omega 3 fatty acids (DHA, EPA) - more than 1 g / day&#xD;
&#xD;
          -  Significant cognitive impairment, clinically relevant or progressive disease (e.g.,&#xD;
             liver, kidney, cardiovascular system, respiratory tract, vascular system, brain,&#xD;
             metabolism, thyroid) that could affect the course of the study&#xD;
&#xD;
          -  Malignant disease&#xD;
&#xD;
          -  Simultaneous participation in an interventional study or participation in an&#xD;
             interventional study in the last two months before study inclusion&#xD;
&#xD;
          -  Clinically relevant addiction or substance abuse disorder (defined as alcohol, drug&#xD;
             and drug abuse)&#xD;
&#xD;
          -  Nicotine consumption of &gt; 5 cigarettes per day and no willingness to stop consumption&#xD;
             during therapeutic fasting.&#xD;
&#xD;
          -  Insufficient mental possibility of cooperation&#xD;
&#xD;
          -  Eating disorder&#xD;
&#xD;
          -  Kidney stones&#xD;
&#xD;
          -  Known metabolic disorders (e.g., fatty acid oxidation disorders, ketolysis /&#xD;
             ketogenesis or glucogenesis disorder, hyperinsulinism (e.g., nesidioblastoma),&#xD;
             pyruvate carboxylase deficiency)&#xD;
&#xD;
          -  Therapy with oral anticoagulants (e.g., Marcumar)&#xD;
&#xD;
          -  Pregnancy and breast feeding period&#xD;
&#xD;
          -  Suspected lack of compliance&#xD;
&#xD;
          -  Performing of a diet for weight reduction&#xD;
&#xD;
          -  Special diet for medical reasons&#xD;
&#xD;
          -  Change of the body weight of more than 5 kg within one month before the start of the&#xD;
             Intervention&#xD;
&#xD;
          -  Medical, psychiatric or other conditions that restrict the patient's following&#xD;
             abilities: to interpret the study information, to give informed consent, to adhere to&#xD;
             the rules of the protocol, or to complete the study&#xD;
&#xD;
          -  Contraindications to MRT examinations [persons with metallic implants (e.g.,&#xD;
             intracranial metal clips) and carriers of electronic devices (e.g., pacemaker) or&#xD;
             persons with claustrophobia]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Relapse-remitting Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

